Henkel, Covestro and Quad Industries collaborate for advanced medical wearables based on printed electronics

Combined capabilities to drive novel healthcare applications presented at MEDICA 2024

Kwality Pharma received approval for Leuprorelin Acetate for injectable suspension from Greece

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25

AbbVie and EvolveImmune Therapeutics collaborate to develop next-generation cancer biotherapeutics

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer

UPM, Selenis and Bormioli Pharma introduce the world's first pharmaceutical bottle partially made with wood-based plastics

The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency

PM Modi launches and inaugurates Rs. 12,850 crore health projects at AIIA, New Delhi

These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide

Lonza extends collaboration with global biopharmaceutical partner for commercial-scale manufacture of ADCs

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC

Lupin appoints Claus Jepsen as President, Global Specialty

Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study

Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies

Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years

Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years